Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors

Two prospective cohort studies (n=10 005, UK; 22 027, USA) found that higher risks of several cardiovascular outcomes among aromatase inhibitors (AIs) compared with tamoxifen users appeared to be driven by protective effects of tamoxifen, rather than cardiotoxic effects of AIs.

Source:

Heart